Herbert Eradat

4.9k total citations
60 papers, 966 citations indexed

About

Herbert Eradat is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Herbert Eradat has authored 60 papers receiving a total of 966 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Genetics, 35 papers in Pathology and Forensic Medicine and 19 papers in Oncology. Recurrent topics in Herbert Eradat's work include Chronic Lymphocytic Leukemia Research (38 papers), Lymphoma Diagnosis and Treatment (35 papers) and CAR-T cell therapy research (12 papers). Herbert Eradat is often cited by papers focused on Chronic Lymphocytic Leukemia Research (38 papers), Lymphoma Diagnosis and Treatment (35 papers) and CAR-T cell therapy research (12 papers). Herbert Eradat collaborates with scholars based in United States, United Kingdom and Germany. Herbert Eradat's co-authors include Thomas J. Kipps, Richard R. Furman, Radhey S. Gupta, Tammy T. Chang, Eli E. Sercarz, Kamal D. Moudgil, Ernest Brahn, Sreeni Yalamanchili, Walter Cosolo and Akiko Chai and has published in prestigious journals such as Circulation, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Herbert Eradat

55 papers receiving 953 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Herbert Eradat United States	17	564	531	270	257	255	60	966
Jerzy Z. Błoński Poland	21	797 1.4×	642 1.2×	403 1.5×	291 1.1×	224 0.9×	75	1.2k
Alicja Gruszka Italy	20	378 0.7×	380 0.7×	112 0.4×	259 1.0×	395 1.5×	36	945
Amit Khot Australia	12	253 0.4×	340 0.6×	180 0.7×	299 1.2×	416 1.6×	53	971
Amanda Copeland United States	15	315 0.6×	558 1.1×	166 0.6×	623 2.4×	536 2.1×	36	1.2k
Magdalena Klánová Czechia	12	252 0.4×	397 0.7×	130 0.5×	346 1.3×	231 0.9×	38	721
Beth Christian United States	18	404 0.7×	682 1.3×	207 0.8×	521 2.0×	132 0.5×	84	979
Sílvia Marcé Spain	12	1.1k 2.0×	877 1.7×	599 2.2×	306 1.2×	458 1.8×	20	1.6k
Floris Dammeijer Netherlands	9	329 0.6×	198 0.4×	429 1.6×	389 1.5×	284 1.1×	15	953
Margaret S. Lucas United States	15	1.2k 2.1×	955 1.8×	610 2.3×	254 1.0×	209 0.8×	34	1.5k
Michael Voralia Canada	11	263 0.5×	309 0.6×	149 0.6×	268 1.0×	229 0.9×	25	681

Countries citing papers authored by Herbert Eradat

Since Specialization

Citations

This map shows the geographic impact of Herbert Eradat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Herbert Eradat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Herbert Eradat more than expected).

Fields of papers citing papers by Herbert Eradat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Herbert Eradat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Herbert Eradat. The network helps show where Herbert Eradat may publish in the future.

Co-authorship network of co-authors of Herbert Eradat

This figure shows the co-authorship network connecting the top 25 collaborators of Herbert Eradat. A scholar is included among the top collaborators of Herbert Eradat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Herbert Eradat. Herbert Eradat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kater, Arnon P., Ann Janssens, Herbert Eradat, et al.. (2024). SINGLE-AGENT EPCORITAMAB LEADS TO DEEP RESPONSES IN PATIENTS (PTS) WITH RICHTER’S TRANSFORMATION (RT): PRIMARY RESULTS FROM THE EPCORE CLL-1 TRIAL. University of Southern Denmark Research Portal (University of Southern Denmark). 1 indexed citations

Tam, Constantine S., Anna Maria Frustaci, Fontanet Bijou, et al.. (2024). Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study. Blood. 144(Supplement 1). 1649–1649. 2 indexed citations

Kater, Arnon P., Ann Janssens, Herbert Eradat, et al.. (2024). Epcoritamab Induces Deep Responses in Patients With Richter Transformation (RT): Primary Results From the EPCORE CLL-1 Trial. Clinical Lymphoma Myeloma & Leukemia. 24. S181–S181. 2 indexed citations

Timmerman, John M., Patricia A. Young, Herbert Eradat, et al.. (2024). Survival benefit of autologous transplant (ASCT) for mantle cell lymphoma (MCL) in the California Cancer Registry (CCR).. Journal of Clinical Oncology. 42(16_suppl). e19043–e19043.

Kater, Arnon P., Ann Janssens, Herbert Eradat, et al.. (2024). CLL-280 Epcoritamab Induces Deep Responses in Patients With Richter Transformation (RT): Primary Results From the EPCORE CLL-1 Trial. Clinical Lymphoma Myeloma & Leukemia. 24. S350–S351. 3 indexed citations

Song, Justin, Jacqueline Vuong, Monica Mead, et al.. (2024). Abstract 4138101: CAR-T-associated Cardiovascular Events are Associated with Increased Resource Utilization. Circulation. 150(Suppl_1).

Seymour, John F., Constantine S. Tam, Chan Y. Cheah, et al.. (2024). Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study. Blood. 144(Supplement 1). 860–860. 9 indexed citations

Eradat, Herbert, Jennifer A. Woyach, Ian W. Flinn, et al.. (2023). Updated follow‐up of BELLWAVE‐001: an open‐label, single‐arm, phase 1/2 study of the efficacy and safety of nemtabrutinib for the treatment of B‐cell malignancies. Hematological Oncology. 41(S2). 565–567. 1 indexed citations

Eichhorst, Barbara, Herbert Eradat, Carsten Utoft Niemann, et al.. (2023). EPCORITAMAB MONOTHERAPY AND COMBINATIONS IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR RICHTER’S SYNDROME: NEW ESCALATION AND EXPANSION COHORTS IN EPCORE CLL‐1. Hematological Oncology. 41(S2). 828–829. 8 indexed citations

10.

Schiller, Gary J., Sven de Vos, Herbert Eradat, et al.. (2021). Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience. Clinical Lymphoma Myeloma & Leukemia. 21(12). 861–872. 17 indexed citations

11.

Wierda, William G., Matthew S. Davids, Bruce D. Cheson, et al.. (2019). Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Haematologica. 104(11). 2258–2264. 28 indexed citations

12.

Montillo, Marco, Árpád Illés, Tadeusz Robak, et al.. (2019). Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial. Health and Quality of Life Outcomes. 17(1). 173–173. 9 indexed citations

13.

Wierda, William G., Matthew S. Davids, Richard R. Furman, et al.. (2017). Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi). Blood. 130. 3025–3025. 3 indexed citations

14.

Mato, Anthony R., William G. Wierda, Matthew S. Davids, et al.. (2017). Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy. Blood. 130(Suppl_1). 834–834. 12 indexed citations

15.

Furman, Richard R., Herbert Eradat, Craig C. Hofmeister, et al.. (2016). Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. The Lancet Haematology. 4(1). e24–e34. 30 indexed citations

16.

Kipps, Thomas J., Herbert Eradat, Sebastian Grosicki, et al.. (2015). A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leukemia & lymphoma. 56(10). 2826–2833. 151 indexed citations

17.

Brown, Jennifer R., Susan O’Brien, Herbert Eradat, et al.. (2015). Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood. 125(18). 2779–2785. 57 indexed citations

18.

Ghia, Paolo, Susan O’Brien, Peter Hillmen, et al.. (2014). Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.. Journal of Clinical Oncology. 32(15_suppl). 7099–7099. 4 indexed citations

19.

Treon, Steven P., Christina Tripsas, Kirsten Meid, et al.. (2013). Prospective, Multicenter Study Of The Mtor Inhibitor Everolimus (RAD001) As Primary Therapy In Waldenstrom’s Macroglobulinemia. Blood. 122(21). 1822–1822. 18 indexed citations

20.

Moudgil, Kamal D., Tammy T. Chang, Herbert Eradat, et al.. (1997). Diversification of T Cell Responses to Carboxy-terminal Determinants within the 65-kD Heat-shock Protein Is Involved in Regulation of Autoimmune Arthritis. The Journal of Experimental Medicine. 185(7). 1307–1316. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact